UIC Department of Psychiatry

Research in the Psychosis Treatment Program

Current treatments for psychosis and schizophrenia are not always as effective as we would hope.  The University of Illinois at Chicago (UIC) Psychosis Treatment Program has an active research program focused on evaluating new pharmacologic and psychosocial treatments that are believed might be more effective or helpful for some people with schizophrenia.

As of early 2012, we are looking at a medication with a new mechanism of action to determine whether it, combined with the patient’s current antipsychotic medication regimen, can be a safe and effective treatment for either persistent negative symptoms or positive psychotic symptoms.

For more information about these studies, you can click the side navigation tabs located on the left of this page. You can also find information about clinical trials of new medications for schizophrenia or psychosis on various websites, especially www.clinicaltrials.gov.

For patients, family members or clinicians who are interested in more information about our current research program, please call (312- 355-5651) or e-mail ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it ).

Our clinical trials team:

  • Peter J. Weiden, M.D., Psychiatrist and Principal Investigator
  • Hugo Solari, M.D., Attending Psychiatrist, Psychosis Treatment Program
  • Sean Conrin, M.D., Chief Resident in Psychiatry
  • Shiyun Kim PharmD, Pharmacist
  • Ben Romanos, M.A. Clinical Coordinator
 
YOU ARE HERE: Home Introduction